Indian Journal of Ophthalmology, Год журнала: 2023, Номер 71(4), С. 1065 - 1066

Опубликована: Апрель 1, 2023

Dry eye disease is a silent modern-age epidemic.[1] It estimated that 280 million people or roughly half of the Indian urban population will be affected by dry year 2030.[2] Therefore, this special issue Journal Ophthalmology timely and relevant. also an opportunity to reflect on what we can do individually collectively reduce burden suffering from disease, which common yet difficult treat. One simplest things, begin with, use term "dry disease" responsibly.[3] Every patient who walks into our clinic complaining dryness does not have eyes, avoiding trap fundamental appropriate diagnosis treatment. The contrary true, patients with may non-specific complaints should miss it, especially preoperatively as it lead dissatisfied despite impeccable cataract refractive surgery.[4] second workshop Tear Film Ocular Surface Society (TFOS DEWS II) has conducted exhaustive exercise in defining collating evidence epidemiology causes, recommendations for treatment.[5] Although there are multitude diagnostic platforms available, most experts agree remains anchored simple clinical tests such fluorescein staining, Schirmer's test, tear break-up time, evaluation meibomian lacrimal glands.[6] role platforms, absence single reliable instrument, largely restricted research. However, imaging provide film meibography metrics part anterior segment profile better investment routine use.[7] average typically unhappy person long list topical medications going one practitioner other looking answers. This needs change. Counseling chair time important aspects treating these patients.[8] facet, attention polypharmacy. Patients often using too many without any reasonable logic. responsibility ensure develop some kind algorithm guide choice lubricating anti-inflammatory formulations. guided novelty claims efficacy made pharmaceutical industry alone. Deprescribing accompanied good measure cessation lubricants, bedrock management, placebo ophthalmic complaint ranging irritation headaches. As medical practitioners, drug formulations responsibly, only if indicated when they likely cause perceptible difference patient's condition. true myriad options drops confusing, evidence-based their need developed. Personalized medicine key problem, biomarkers us toward choosing right molecule each individual patient.[9,10] reassuring research happening India, soon able make more informed choices. step therapy correctly identifying dominant sub-type patient. mixed etiology common, primary involvement either glands.[8,11] differentiation clinically, sophisticated gadgets, clarifies prognosis systemic medications. Several medications, both systemic, responsible causing exaggerating therefore ruled out.[12] Stopping offending agents cases completely resolve all symptoms, no treatment required. Some adjunctive therapies immunosuppression, scleral contact lenses, autologous serum eyedrops overlooked significant relief used judiciously.[13–15] Newer approaches regenerative medicine, biomaterials, nano-formulations horizon, alternative solutions condition.[16] magnitude diversity underlying spectrum presentation challenging conundrum solve observation skill Wherever resources must undertaken unravel mechanisms creating studying models[17,18] identify potential therapeutic targets, novel therapies. Greater collaboration between academic institutions researchers absolute necessity close partnership industry. tempting think day miracle cure condition, unlikely. Simply because umbrella variety conditions instability ocular surface inflammation. diagnosing someone qualifying sub-type, attempt elucidate cause. Treatment, then follows reverse order, addressing targeted glands,[19] improve desiccation showcases breadth depth ongoing puts together experience-based reviews preferred practice pattern guidelines, fantastic resource subject general practitioners cornea specialists alike. With innovative answers future, work create consensus rational guidelines helping those afflicted disease. About authorDr Sayan Basu Dr Prof. D Balasubramanian Chair Eye Research, Director Brien Holden Research Centre (BHERC), Regeneration (CORE) at LV Prasad Institute (LVPEI), Hyderabad. He clinician-scientist opinion leader field surface, internationally recognized his breakthroughs corneal stem cell therapy. His specific interests include scarless wound healing, therapy, renowned national international scientists. After completing education R G Kar Medical College residency training Regional Ophthalmology, Kolkata, Dr. completed long-term fellowship LVPEI, Hyderabad, subsequently joined faculty institute 2010. received biology University Pittsburgh School Medicine, PA, USA 2012-13. been honored Achievement Award American Academy serves editorial board several prestigious scientific journals. published than 200 papers, highly cited ophthalmology visual sciences community. believes patient-centric care, personalized developed through needed help

Язык: Английский